Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma

被引：6
|
作者：
Sano, Renata [1 ]
Krytska, Kateryna [1 ]
Tsang, Matthew [1 ]
Erickson, Stephen W. [2 ]
Teicher, Beverly A. [3 ]
Saunders, Laura [4 ]
Jones, Ryan T. [4 ]
Smith, Malcom A. [3 ]
Maris, John M. [1 ]
Mosse, Yael P. [1 ]
机构：
[1] CHOP, Philadelphia, PA USA
[2] RTI Int, Res Triangle Pk, NC USA
[3] NCI, Bethesda, MD 20892 USA
[4] Abbvie, San Francisco, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-136
引用
收藏
页数：2
相关论文
共 39 条
  • [1] Evaluation of the DLL3-targeting Antibody-Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
    Krytska, Kateryna
    Casey, Colleen E.
    Pogoriler, Jennifer
    Martinez, Daniel
    Rathi, Komal S.
    Farrel, Alvin
    Berko, Esther R.
    Tsang, Matthew
    Sano, Renata R.
    Kendsersky, Nathan
    Erickson, Stephen W.
    Teicher, Beverly A.
    Isse, Kumiko
    Saunders, Laura
    Smith, Malcolm A.
    Maris, John M.
    Mosse, Yael P.
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (07): : 616 - 623
  • [2] Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
    Bilal H. Lashari
    Yazhini Vallatharasu
    Lakshmi Kolandra
    Mohsin Hamid
    Dipesh Uprety
    Drugs in R&D, 2018, 18 : 255 - 258
  • [3] Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate
    Lashari, Bilal H.
    Vallatharasu, Yazhini
    Kolandra, Lakshmi
    Hamid, Mohsin
    Uprety, Dipesh
    DRUGS IN R&D, 2018, 18 (04) : 255 - 258
  • [4] Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC
    Bauer, Todd M.
    Spigel, David
    Ready, Neal
    Morgensztern, Daniel
    Glisson, Bonnie S.
    Byers, Lauren A.
    Burris, Howard
    Robert, Francisco
    Strickland, Donald K.
    Pietanza, Maria C.
    Govindan, Ramaswamy
    Dylla, Scott J.
    Peng, Stanford
    Rudin, Charles
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S252 - S253
  • [5] A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC
    Rudin, Charles M.
    Pietanza, M. Catherine
    Spigel, David R.
    Bauer, T. M.
    Glisson, Bonnie
    Robert, Francisco
    Ready, Neal
    Morgensztern, Daniel
    Kochendoerfer, Mark D.
    Patel, Manish
    Salgia, Ravi
    Strickland, Donald K.
    Govindan, Ramaswamy
    Burris, Howard
    Dylla, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S192 - S193
  • [6] Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
    Rudin, Charles M.
    Pietanza, M. Catherine
    Bauer, Todd M.
    Ready, Neal
    Morgensztern, Daniel
    Glisson, Bonnie S.
    Byers, Lauren A.
    Johnson, Melissa L.
    Burris, Howard A., III
    Robert, Francisco
    Han, Tae H.
    Bheddah, Sheila
    Theiss, Noah
    Watson, Sky
    Mathur, Deepan
    Vennapusa, Bharathi
    Zayed, Hany
    Lally, Satwant
    Strickland, Donald K.
    Govindan, Ramaswamy
    Dylla, Scott J.
    Peng, Stanford L.
    Spigel, David R.
    LANCET ONCOLOGY, 2017, 18 (01): : 42 - 51
  • [7] Rovalpituzumab tesirine Antibody-drug conjugate targeting delta-like protein 3 (DLL3) Treatment of small cell lung cancer
    Gras, J.
    DRUGS OF THE FUTURE, 2018, 43 (04) : 261 - 265
  • [8] Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
    Spigel, David
    Pietanza, M. Catherine
    Bauer, Todd
    Ready, Neal
    Morgensztern, Daniel
    Glisson, Bonnie S.
    Byers, Lauren Averett
    Johnson, Melissa
    Burris, Howard
    Robert, Francisco
    Han, Tae
    Bheddah, Sheila
    Theiss, Noah
    Watson, Sky
    Mathur, Deepan
    Vennapusa, Bharathi
    Strickland, Donald
    Zayed, Hany
    Dylla, Scott
    Peng, Stanford
    Govindan, Ramaswamy
    Rudin, Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S260 - S261
  • [9] FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
    Guo, Qingsong
    Gao, Bei
    Song, Ruiwen
    Li, Weinan
    Zhu, Shulei
    Xie, Qian
    Lou, Sensen
    Wang, Lei
    Shen, Jiafei
    Zhao, Teng
    Zhang, Yifan
    Wu, Jinsong
    Lu, Wei
    Yang, Tong
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1367 - 1377
  • [10] Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)
    Pietanza, M. C.
    Spigel, D.
    Bauer, T. M.
    Ready, N. E.
    Glisson, B. S.
    Morgensztern, D.
    Robert, F.
    Salgia, R.
    Kochendorfer, M.
    Patel, M.
    Strickland, D. K.
    Govindan, R.
    Burris, H. A.
    Rudin, C. M.
    Dylla, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S712 - S712
1234